Evidence map›Paper›PMID 39636841›Full record

ArticlePloS one2024

Understanding tuberculosis transmission and progression: A prospective cohort study of index cases and close contacts in Moldova.

Rehan R Syed, Donald G Catanzaro, Naomi Hillery, Valeriu Crudu, Elena Tudor, Nelly Ciobanu, Alexandru Codreanu, Maryam Kheirandish Borujeni, Antonino Catanzaro, Timothy C Rodwell

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rehan R SyedDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, United States of America.ORCID 0000-0001-8898-7388
Donald G CatanzaroDepartment of Biological Sciences, University of Arkansas, Fayetteville, AR, United States of America.
Naomi HilleryThe Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, United States of America.
Valeriu CruduThe Institute of Phthisiopneumology "Chiril Draganiuc," Chisinau, Republic of Moldova.ORCID 0000-0001-5059-8002
Elena TudorThe Institute of Phthisiopneumology "Chiril Draganiuc," Chisinau, Republic of Moldova.
Nelly CiobanuThe Institute of Phthisiopneumology "Chiril Draganiuc," Chisinau, Republic of Moldova.
Alexandru CodreanuThe Institute of Phthisiopneumology "Chiril Draganiuc," Chisinau, Republic of Moldova.ORCID 0000-0002-7331-8138
Maryam Kheirandish BorujeniDepartment of Industrial Engineering, University of Arkansas, Fayetteville, Arkansas, United States of America.
Antonino CatanzaroDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of California San Diego, La Jolla, CA, United States of America.
Timothy C RodwellDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of California San Diego, La Jolla, CA, United States of America.

Funding

HOPE Training GrantT32AI007384 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sara Gianella Weibel, Scott L Letendre · 1990 to 2026
$9.7M
Identifying individuals at risk of progression to active tuberculosisR01AI137681 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CATANZARO, ANTONINO, RODWELL, TIMOTHY CHARLES · 2018 to 2022
$3.7M
NIAID NIH HHS R01 AI137681NIAID NIH HHS T32 AI007384
6 · The paper itself

Abstract

objectivesThis study aims to determine the progression rate, risk factors and timeline for the progression from exposure to active tuberculosis (TB) in a high-risk population. Using a prospective cohort in the Republic of Moldova, we investigated pulmonary TB disease progression among close contacts of patients with TB in a low-burden country with high rates of drug-resistant TB.

methodsClose contacts of patients with newly diagnosed TB were recruited and monitored to evaluate for progression rates to active TB. Data collected included demographic information, medical and exposure history, and clinical samples. Follow-up clinical evaluations of close contacts were conducted at regular intervals over at least 24 months to monitor for progression to TB disease.

resultsThe overall incidence rate of TB disease among close contacts was 3.7%. Among the close contacts, 2.3% were identified as progressor cases, developing TB disease more than 30 days after index case treatment initiation. Thirteen (1.3%) were co-prevalent cases, diagnosed within 30 days of index case treatment initiation. Identified risk factors for progression included male sex, active tobacco use, prior TB infection, and frequent, prolonged exposure to index cases. Close contacts with daily exposure of more than eight hours had a significantly higher risk of disease progression (adjusted OR: 4.28, 95% CI: 1.79-10.23).

conclusionThe incidence of TB disease among close contacts was consistent with global findings, highlighting the need for enhanced diagnostic tools and targeted interventions to manage TB transmission and progression. These results underscore the importance of contact tracing and progression monitoring in low-burden, high drug-resistant TB settings. Future research should focus on developing a better understanding of factors contributing to the risk for and timeline of TB disease progression, and more precise methods, including biomarkers, to identify individuals at the highest risk for progression from TB exposure to active disease.

Indexed as

Disease ProgressionAdolescentAdultAgedChildContact TracingFemaleHumansIncidenceMaleMiddle AgedMoldovaProspective StudiesRisk FactorsTuberculosisTuberculosis, Pulmonary

Identifiers

PMID39636841
PMCPMC11620447

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.